These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets. Mellado B; Marin Aguilera M; Pereira MV Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763 [TBL] [Abstract][Full Text] [Related]
27. [Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer]. Hupe MC; Offermann A; Perabo F; Chandhasin C; Perner S; Merseburger AS; Cronauer MV Urologe A; 2018 Feb; 57(2):148-154. PubMed ID: 29147733 [TBL] [Abstract][Full Text] [Related]
28. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603 [TBL] [Abstract][Full Text] [Related]
29. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor. Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338 [TBL] [Abstract][Full Text] [Related]
30. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. Vis AN; Schröder FH BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559 [TBL] [Abstract][Full Text] [Related]
31. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Mitsiades N Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973 [TBL] [Abstract][Full Text] [Related]
32. Recent androgen receptor antagonists in prostate cancer. Lu X; Dun K; Wang Y; Yang Y; You Q; Li Z Mini Rev Med Chem; 2014; 14(8):655-63. PubMed ID: 24958215 [TBL] [Abstract][Full Text] [Related]
33. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578 [TBL] [Abstract][Full Text] [Related]
34. Androgen receptor modulators: a review of recent patents and reports (2012-2018). Fujii S; Kagechika H Expert Opin Ther Pat; 2019 Jun; 29(6):439-453. PubMed ID: 31092069 [TBL] [Abstract][Full Text] [Related]
35. Recent advances in understanding hormonal therapy resistant prostate cancer. Donkena KV; Yuan H; Young CY Curr Cancer Drug Targets; 2010 Jun; 10(4):402-10. PubMed ID: 20464780 [TBL] [Abstract][Full Text] [Related]
37. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells. Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604 [TBL] [Abstract][Full Text] [Related]
38. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy. Gianti E; Zauhar RJ J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551 [TBL] [Abstract][Full Text] [Related]